Mimedx Group Inc (NASDAQ: MDXG) closed the day trading at $6.90 down -1.43% from the previous closing price of $7.00. In other words, the price has decreased by -$0.10 from its previous closing price. On the day, 620254 shares were traded.
Ratios:
For a better understanding of MDXG, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.37 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 40.90. For the most recent quarter (mrq), Quick Ratio is recorded 3.11 and its Current Ratio is at 3.57. In the meantime, Its Debt-to-Equity ratio is 0.35 whereas as Long-Term Debt/Eq ratio is at 0.34.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Lake Street on March 07, 2024, initiated with a Buy rating and assigned the stock a target price of $12.
On October 27, 2023, Craig Hallum started tracking the stock assigning a Buy rating and target price of $12.
On October 13, 2022, Mizuho started tracking the stock assigning a Buy rating and target price of $7.Mizuho initiated its Buy rating on October 13, 2022, with a $7 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 13 ’24 when Hulse William Frank IV sold 20,381 shares for $7.95 per share. The transaction valued at 162,029 led to the insider holds 479,959 shares of the business.
Whitlow Ricci S sold 15,271 shares of MDXG for $122,351 on Feb 20 ’24. The Chief Operating Officer now owns 401,050 shares after completing the transaction at $8.01 per share. On Feb 16 ’24, another insider, Whitlow Ricci S, who serves as the Chief Operating Officer of the company, sold 15,493 shares for $8.07 each. As a result, the insider received 125,075 and left with 416,321 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MDXG now has a Market Capitalization of 1.02B and an Enterprise Value of 981.58M. As of this moment, Mimedx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 20.03, and their Forward P/E ratio for the next fiscal year is 16.05. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.34. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.15 while its Price-to-Book (P/B) ratio in mrq is 7.07. Its current Enterprise Value per Revenue stands at 3.05 whereas that against EBITDA is 24.23.
Stock Price History:
Over the past 52 weeks, MDXG has reached a high of $9.27, while it has fallen to a 52-week low of $3.13. The 50-Day Moving Average of the stock is 7.90, while the 200-Day Moving Average is calculated to be 7.54.
Shares Statistics:
Over the past 3-months, MDXG traded about 766.41K shares per day on average, while over the past 10 days, MDXG traded about 955.64k shares per day. A total of 146.23M shares are outstanding, with a floating share count of 104.04M. Insiders hold about 29.21% of the company’s shares, while institutions hold 41.67% stake in the company. Shares short for MDXG as of Mar 15, 2024 were 5.52M with a Short Ratio of 7.21, compared to 4.88M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.76% and a Short% of Float of 3.79%.
Earnings Estimates
Current recommendations for the stock of the company come from 6 analysts. On average, analysts expect EPS of $0.04 for the current quarter, with a high estimate of $0.06 and a low estimate of $0.03, while EPS last year was -$0.06. The consensus estimate for the next quarter is $0.08, with high estimates of $0.1 and low estimates of $0.07.
Analysts are recommending an EPS of between $0.35 and $0.28 for the fiscal current year, implying an average EPS of $0.31. EPS for the following year is $0.39, with 5 analysts recommending between $0.44 and $0.35.
Revenue Estimates
6 analysts predict $79.36M in revenue for the current quarter. It ranges from a high estimate of $80M to a low estimate of $79M. As of the current estimate, Mimedx Group Inc’s year-ago sales were $64.15M, an estimated increase of 23.70% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $89M, an increase of 9.50% less than the figure of $23.70% in the same quarter last year. There is a high estimate of $91M for the next quarter, whereas the lowest estimate is $87M.
A total of 6 analysts have provided revenue estimates for MDXG’s current fiscal year. The highest revenue estimate was $363.21M, while the lowest revenue estimate was $354.1M, resulting in an average revenue estimate of $357.12M. In the same quarter a year ago, actual revenue was $321.48M, up 11.10% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $403.37M in the next fiscal year. The high estimate is $419.19M and the low estimate is $392.1M. The average revenue growth estimate for next year is up 13.00% from the average revenue estimate for this year.
